BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43:603-617. [PMID: 25110261 DOI: 10.1016/j.gtc.2014.05.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Argollo M, Fiorino G, Hindryckx P, Peyrin-biroulet L, Danese S. Novel therapeutic targets for inflammatory bowel disease. Journal of Autoimmunity 2017;85:103-16. [DOI: 10.1016/j.jaut.2017.07.004] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 11.8] [Reference Citation Analysis]
2 Lu Q, Yang M, Liang Y, Xu J, Xu H, Nie Y, Wang L, Yao J, Li D. Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics. JIR 2022;Volume 15:1825-44. [DOI: 10.2147/jir.s353038] [Reference Citation Analysis]
3 Juncadella AC, Alame AM, Sands LR, Deshpande AR. Perianal Crohn’s disease: A review. Postgraduate Medicine 2015;127:266-72. [DOI: 10.1080/00325481.2015.1023160] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
4 Danese S, Grisham M, Hodge J, Telliez JB. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016;310:G155-G162. [PMID: 26608188 DOI: 10.1152/ajpgi.00311.2015] [Cited by in Crossref: 86] [Cited by in F6Publishing: 74] [Article Influence: 12.3] [Reference Citation Analysis]
5 Singer JW, Al-Fayoumi S, Taylor J, Velichko S, O'Mahony A. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures. PLoS One 2019;14:e0222944. [PMID: 31560729 DOI: 10.1371/journal.pone.0222944] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
6 Teixeira FV, Damião AOMC, Kotze PG. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES. Arq Gastroenterol 2018;55:198-200. [PMID: 30043874 DOI: 10.1590/S0004-2803.201800000-36] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Furfaro F, Fiorino G, Allocca M, Gilardi D, Danese S. Emerging therapeutic targets and strategies in Crohn's disease. Expert Rev Gastroenterol Hepatol 2016;10:735-44. [PMID: 26766496 DOI: 10.1586/17474124.2016.1142372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Hvas CL, Bendix M, Dige A, Dahlerup JF, Agnholt J. Current, experimental, and future treatments in inflammatory bowel disease: a clinical review. Immunopharmacol Immunotoxicol 2018;40:446-60. [PMID: 29745777 DOI: 10.1080/08923973.2018.1469144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
9 Ding N, Miller SA, Savant SS, O'hagan HM. JAK2 regulates mismatch repair protein‐mediated epigenetic alterations in response to oxidative damage. Environ Mol Mutagen 2019;60:308-19. [DOI: 10.1002/em.22269] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
10 Vetter M, Neurath M. Treatment Perspectives in Crohn’s Disease. Digestion 2018;98:135-42. [DOI: 10.1159/000488449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Palasik BN, Wang H. Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis. J Pharm Pract 2020;:897190020953019. [PMID: 32873116 DOI: 10.1177/0897190020953019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Samson M, Greigert H, Ghesquière T, Bonnotte B. [Treatment of giant cell arteritis]. Presse Med 2019;48:968-79. [PMID: 31324351 DOI: 10.1016/j.lpm.2019.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Taxonera C, Olivares D, Alba C. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. Inflamm Bowel Dis 2021:izab011. [PMID: 33586766 DOI: 10.1093/ibd/izab011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
14 Vetter M, Neurath MF. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therap Adv Gastroenterol 2017;10:773-90. [PMID: 29051788 DOI: 10.1177/1756283X17727388] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
15 Tanaka Y, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Combe BG, Kivitz AJ, Bae SC, Keystone EC, Nash P, Matzkies F, Bartok B, Pechonkina A, Kondo A, Ye L, Guo Y, Tasset C, Sundy JS, Takeuchi T. Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). Mod Rheumatol 2021:roab030. [PMID: 34910188 DOI: 10.1093/mr/roab030] [Reference Citation Analysis]
16 Sandborn WJ, Nguyen DD, Beattie DT, Brassil P, Krey W, Woo J, Situ E, Sana R, Sandvik E, Pulido-Rios MT, Bhandari R, Leighton JA, Ganeshappa R, Boyle DL, Abhyankar B, Kleinschek MA, Graham RA, Panes J. Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme. J Crohns Colitis 2020;14:1202-13. [PMID: 32161949 DOI: 10.1093/ecco-jcc/jjaa049] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
17 Yin T, Chen S, Wu X, Tian W. GenePANDA-a novel network-based gene prioritizing tool for complex diseases. Sci Rep 2017;7:43258. [PMID: 28252032 DOI: 10.1038/srep43258] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
18 Tindemans I, Joosse ME, Samsom JN. Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD. Cells 2020;9:E110. [PMID: 31906479 DOI: 10.3390/cells9010110] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
19 Olivera P, Danese S, Peyrin-biroulet L. JAK inhibition in inflammatory bowel disease. Expert Review of Clinical Immunology 2017;13:693-703. [DOI: 10.1080/1744666x.2017.1291342] [Cited by in Crossref: 46] [Cited by in F6Publishing: 20] [Article Influence: 9.2] [Reference Citation Analysis]
20 Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269-278. [PMID: 28144028 DOI: 10.1038/nrgastro.2016.208] [Cited by in Crossref: 214] [Cited by in F6Publishing: 208] [Article Influence: 42.8] [Reference Citation Analysis]
21 Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, Klopocka M, Goldis A, Wisniewska-Jarosinska M, Baranovsky A, Sike R, Stoyanova K, Tasset C, Van der Aa A, Harrison P. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266-275. [PMID: 27988142 DOI: 10.1016/s0140-6736(16)32537-5] [Cited by in Crossref: 208] [Cited by in F6Publishing: 75] [Article Influence: 34.7] [Reference Citation Analysis]
22 Sharara AI, Al Awadhi S, Alharbi O, Al Dhahab H, Mounir M, Salese L, Singh E, Sunna N, Tarcha N, Mosli M. Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East. Expert Rev Gastroenterol Hepatol. 2018;12:883-897. [PMID: 30096985 DOI: 10.1080/17474124.2018.1503052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
23 Leonard KA, Madge LA, Krawczuk PJ, Wang A, Kreutter KD, Bacani GM, Chai W, Smith RC, Tichenor MS, Harris MC, Malaviya R, Seierstad M, Johnson ME, Venable JD, Kim S, Hirst GC, Mathur AS, Rao TS, Edwards JP, Rizzolio MC, Koudriakova T. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem 2020;63:2915-29. [DOI: 10.1021/acs.jmedchem.9b01439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Nielsen OH, Boye TL, Chakravarti D, Gubatan J. Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. Trends Pharmacol Sci 2022:S0165-6147(22)00032-3. [PMID: 35277286 DOI: 10.1016/j.tips.2022.02.008] [Reference Citation Analysis]
25 Wang YL, Fang M, Wang XM, Liu WY, Zheng YJ, Wu XB, Tao R. Proinflammatory effects and molecular mechanisms of interleukin-17 in intestinal epithelial cell line HT-29. World J Gastroenterol 2014; 20(47): 17924-17931 [PMID: 25548490 DOI: 10.3748/wjg.v20.i47.17924] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
26 Chang S, Hanauer S. Optimizing pharmacologic management of inflammatory bowel disease. Expert Review of Clinical Pharmacology 2017;10:595-607. [DOI: 10.1080/17512433.2017.1318062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
27 Varyani F, Argyriou K, Phillips F, Tsakiridou E, Moran GW. Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data. Drug Des Devel Ther 2019;13:4091-105. [PMID: 31819376 DOI: 10.2147/DDDT.S182891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
28 Kumalo HM, Bhakat S, Soliman ME. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective. Chem Biol Drug Des 2015;86:1131-60. [PMID: 25958815 DOI: 10.1111/cbdd.12582] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
29 Paschos P, Katsoula A, Giouleme O, Sarigianni M, Liakos A, Athanasiadou E, Bekiari E, Tsapas A. Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Ann Gastroenterol 2018;31:572-82. [PMID: 30174394 DOI: 10.20524/aog.2018.0276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
30 Nagy-Szakal D, Mir SA, Harris RA, Dowd SE, Yamada T, Lacorazza HD, Tatevian N, Smith CW, de Zoeten EF, Klein J, Kellermayer R. Loss of n-6 fatty acid induced pediatric obesity protects against acute murine colitis. FASEB J 2015;29:3151-9. [PMID: 25903104 DOI: 10.1096/fj.14-267690] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
31 White JR, Phillips F, Monaghan T, Fateen W, Samuel S, Ghosh S, Moran GW. Review article: novel oral-targeted therapies in inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47:1610-1622. [PMID: 29672874 DOI: 10.1111/apt.14669] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
32 Salehi B, Shivaprasad Shetty M, V Anil Kumar N, Živković J, Calina D, Oana Docea A, Emamzadeh-Yazdi S, Sibel Kılıç C, Goloshvili T, Nicola S, Pignata G, Sharopov F, Del Mar Contreras M, Cho WC, Martins N, Sharifi-Rad J. Veronica Plants-Drifting from Farm to Traditional Healing, Food Application, and Phytopharmacology. Molecules 2019;24:E2454. [PMID: 31277407 DOI: 10.3390/molecules24132454] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
33 Majchrzak K, Fichna J. Biologic Therapy in Crohn's Disease-What We Have Learnt So Far. Curr Drug Targets 2020;21:792-806. [PMID: 31854272 DOI: 10.2174/1389450121666191218123203] [Reference Citation Analysis]
34 Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 2021;397:2372-84. [PMID: 34090625 DOI: 10.1016/S0140-6736(21)00666-8] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Wendling D, Prati C. Kinases inhibitors and small molecules: A new treatment tool for axial spondyloarthropathy? Joint Bone Spine 2016;83:473-5. [DOI: 10.1016/j.jbspin.2016.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
36 Davies SC, Hussein IM, Nguyen TM, Parker CE, Khanna R, Jairath V. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;1:CD012381. [PMID: 31984480 DOI: 10.1002/14651858.CD012381.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Lohan C, Diamantopoulos A, LeReun C, Wright E, Bohm N, Sawyer LM. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol 2019;6:e000302. [PMID: 31413856 DOI: 10.1136/bmjgast-2019-000302] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
38 Li Y, Yao C, Xiong Q, Xie F, Luo L, Li T, Feng P. Network meta‐analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis. Clinical Pharmacy Therapeu. [DOI: 10.1111/jcpt.13622] [Reference Citation Analysis]
39 Cohen NA, Rubin DT. New targets in inflammatory bowel disease therapy: 2021. Curr Opin Gastroenterol 2021;37:357-63. [PMID: 34059604 DOI: 10.1097/MOG.0000000000000740] [Reference Citation Analysis]
40 Nielsen OH, Seidelin JB, Ainsworth M, Coskun M. Will novel oral formulations change the management of inflammatory bowel disease? Expert Opin Investig Drugs 2016;25:709-18. [PMID: 26967267 DOI: 10.1517/13543784.2016.1165204] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]